080720 — Union Korea Pharm Co Balance Sheet
0.000.00%
HealthcareSpeculativeMicro Cap
Annual balance sheet for Union Korea Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,898 | 20,745 | 6,142 | 6,690 | 4,546 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 27,085 | 26,796 | 33,725 | 34,278 | 20,808 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 44,045 | 58,782 | 54,570 | 49,683 | 40,198 |
| Net Property, Plant And Equipment | 39,996 | 43,787 | 44,613 | 34,596 | 28,659 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 97,183 | 119,044 | 112,523 | 94,425 | 74,900 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 23,026 | 44,477 | 58,992 | 59,009 | 63,949 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 28,814 | 66,703 | 63,910 | 64,101 | 66,651 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 68,369 | 52,341 | 48,612 | 30,324 | 8,249 |
| Total Liabilities & Shareholders' Equity | 97,183 | 119,044 | 112,523 | 94,425 | 74,900 |
| Total Common Shares Outstanding |